Advertisement

A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial

Published:February 09, 2022DOI:https://doi.org/10.1016/j.hpb.2022.02.001

      Abstract

      Background

      The effect of bevacizumab plus mFOLFOX6 on downsizing of liver metastases for curative resection has not been well assessed for patients with advanced colorectal liver metastases (CRLMs). This multicenter phase II trial aimed to examine the efficacy and safety of bevacizumab plus mFOLFOX6 for advanced CRLMs harboring mutant-type KRAS.

      Methods

      Patients with advanced CRLMs (tumor number of ≥5 and/or technically unresectable) harboring mutant-type KRAS were included. Surgical indication was evaluated every 4 cycles of bevacizumab plus mFOLFOX6. Liver resection was planned if the CRLMs were resectable. The primary endpoint was R0 resection rate. The secondary endpoints included overall survival (OS), recurrence-free survival, progression-free survival, and safety.

      Results

      Between 2013 and 2017, 29 patients from six centers were registered. The rates of complete and partial responses were 0% and 62.1%, respectively. R0 and R1 resections were performed in 19 and 1 patient, respectively (R0 resection rate: 65.5%). No mortality occurred. During the median follow-up of 30.7 months, the 3-year OS rate for all the patients was 64.4% with the median survival of 49.1 months.

      Conclusion

      For advanced CRLMs harboring mutant-type KRAS, bevacizumab plus mFOLFOX6 achieved a high R0 resection rate, leading to favorable survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cummings L.C.
        • Payes J.D.
        • Cooper G.S.
        Survival after hepatic resection in metastatic colorectal cancer: a population-based study.
        Cancer. 2007; 109: 718-726
        • Nathan H.
        • de Jong M.C.
        • Pulitano C.
        • Ribero D.
        • Strub J.
        • Mentha G.
        • et al.
        Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients.
        J Am Coll Surg. 2010; 210: 755-766
        • Scheele J.
        • Stangl R.
        • Altendorf-Hofmann A.
        Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.
        Br J Surg. 1990; 77: 1241-1246
        • Scheele J.
        Hepatectomy for liver metastases.
        Br J Surg. 1993; 80: 274-276
        • Adam R.
        • Wicherts D.A.
        • de Haas R.J.
        • Ciacio O.
        • Levi F.
        • Paule B.
        • et al.
        Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?.
        J Clin Oncol. 2009; 27: 1829-1835
        • Devaud N.
        • Kanji Z.S.
        • Dhani N.
        • Grant R.C.
        • Shoushtari H.
        • Serrano P.E.
        • et al.
        Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
        HPB. 2014; 16: 475-480
        • Adam R.
        • Delvart V.
        • Pascal G.
        • Valeanu A.
        • Castaing D.
        • Azoulay D.
        • et al.
        Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
        Ann Surg. 2004; 240: 644-657
        • Wong R.
        • Cunningham D.
        • Barbachano Y.
        • Saffery C.
        • Valle J.
        • Hickish T.
        • et al.
        A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
        Ann Oncol. 2011; 22: 2042-2048
        • Beppu T.
        • Emi Y.
        • Tokunaga S.
        • Oki E.
        • Shirabe K.
        • Ueno S.
        • et al.
        Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study).
        Anticancer Res. 2014; 34: 6655-6662
        • Mise Y.
        • Hasegawa K.
        • Saiura A.
        • Oba M.
        • Yamamoto J.
        • Nomura Y.
        • et al.
        A multicenter phase 2 trial to evaluate the efficacy of mFOLFOX6 + cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial).
        Ann Surg Oncol. 2020; 27: 4188-4195
        • Hatano E.
        • Okuno M.
        • Nakamura K.
        • Ishii T.
        • Seo S.
        • Taura K.
        • et al.
        Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
        J Hepatobiliary Pancreat Sci. 2015; 22: 634-645
        • Tang W.
        • Ren L.
        • Liu T.
        • Ye Q.
        • Wei Y.
        • He G.
        • et al.
        Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial.
        J Clin Oncol. 2020; 38: 3175-3184
        • Adam R.
        • De Gramont A.
        • Figueras J.
        • Guthrie A.
        • Kokudo N.
        • Kunstlinger F.
        • et al.
        The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
        Oncologist. 2012; 17: 1225-1239
        • Folprecht G.
        • Gruenberger T.
        • Bechstein W.
        • Raab H.R.
        • Weitz J.
        • Lordick F.
        • et al.
        Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
        Ann Oncol. 2014; 25: 1018-1025
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • Sobrero A.
        • Van Krieken J.H.
        • Aderka D.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Tournigand C.
        • André T.
        • Achille E.
        • Lledo G.
        • Flesh M.
        • Mery-Mignard D.
        • et al.
        FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
        J Clin Oncol. 2004; 22: 229-237
        • Folprecht G.
        • Gruenberger T.
        • Bechstein W.O.
        • Raab H.-R.
        • Lordick F.
        • Hartmann J.T.
        • et al.
        Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
        Lancet Oncol. 2010; 11: 38-47
        • Fong Y.
        • Gonen M.
        • Rubin D.
        • Radzyner M.
        • Brennan M.F.
        Long-term survival is superior after resection for cancer in high-volume centers.
        Ann Surg. 2005; 242: 540-544
        • Jones R.P.
        • Vauthey J.N.
        • Adam R.
        • Rees M.
        • Berry D.
        • Jackson R.
        • et al.
        Effect of specialist decision-making on treatment strategies for colorectal liver metastases.
        Br J Surg. 2012; 99: 1263-1269
        • Mise Y.
        • Aloia T.A.
        • Brudvik K.W.
        • Schwarz L.
        • Vauthey J.N.
        • Conrad C.
        Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival.
        Ann Surg. 2016; 263: 146-152
        • Gruenberger T.
        • Bridgewater J.
        • Chau I.
        • Garcia Alfonso P.
        • Rivoire M.
        • Mudan S.
        • et al.
        Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
        Ann Oncol. 2015; 26: 702-708
        • Uetake H.
        • Yasuno M.
        • Ishiguro M.
        • Kameoka S.
        • Shimada Y.
        • Takahashi K.
        • et al.
        A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
        Ann Surg Oncol. 2015; 22: 908-915
        • Vauthey J.N.
        • Zimmitti G.
        • Kopetz S.E.
        • Shindoh J.
        • Chen S.S.
        • Andreou A.
        • et al.
        RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
        Ann Surg. 2013; 258: 619-626
        • Margonis G.A.
        • Spolverato G.
        • Kim Y.
        • Karagkounis G.
        • Choti M.A.
        • Pawlik T.M.
        Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases.
        Ann Surg Oncol. 2015; 22: 4158-4165
        • Shindoh J.
        • Nishioka Y.
        • Yoshioka R.
        • Sugawara T.
        • Sakamoto Y.
        • Hasegawa K.
        • et al.
        KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion.
        Ann Surg Oncol. 2016; 23: 1890-1896
        • Krell R.W.
        • Reames B.N.
        • Hendren S.
        • Frankel T.L.
        • Pawlik T.M.
        • Chung M.
        • et al.
        Surgical referral for colorectal liver metastases: a population-based survey.
        Ann Surg Oncol. 2015; 22: 2179-2194
        • Engstrand J.
        • Kartalis N.
        • Stromberg C.
        • Broberg M.
        • Stillstrom A.
        • Lekberg T.
        • et al.
        The impact of a hepatobiliary multidisciplinary team assessment in patients with colorectal cancer liver metastases: a population-based study.
        Oncologist. 2017; 22: 1067-1074
        • Vallance A.E.
        • vanderMeulen J.
        • Kuryba A.
        • Botterill I.D.
        • Hill J.
        • Jayne D.G.
        • et al.
        Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases.
        Br J Surg. 2017; 104: 918-925
        • Idrees J.J.
        • Johnston F.M.
        • Canner J.K.
        • Dillhoff M.
        • Schmidt C.
        • Haut E.R.
        • et al.
        Cost of major complications after liver resection in the United States: are high-volume centers cost-effective?.
        Ann Surg. 2019; 269: 503-510